Anapole Technologies

Executive Summary

Anapole Technologies is a preclinical biotech company based in Cambridge, MA, developing a non-invasive therapeutic and diagnostic platform using its patented Resonance Generating Fields (RGFields) technology. Founded in 2019, the company targets incurable diseases such as HIV, tuberculosis, and aggressive cancers, aiming to provide affordable, rapid treatments with minimal side effects. The platform integrates hardware and software currently in its sixth generation, designed to detect, diagnose, and treat diseases through electromagnetic fields. As a private, early-stage company, Anapole has not disclosed funding or valuation, but its novel approach could address significant unmet medical needs if validated in clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data readout in HIV or oncology models60% success
• Q4 2026Strategic partnership or licensing deal with a pharmaceutical company40% success
• Q2 2026Series A financing round to support IND-enabling studies50% success